MediPharm Labs (MLZ) Q2 2026 Earnings Report

The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.

Management's guidance emphasized disciplined, margin‑focused growth in 2026 and beyond—prioritizing regulated medical markets, selective M&A, geographic expansion (France, Brazil, New Zealand, U.K.), and non‑smokable/pharma formats (oils and a metered‑dose inhaler dossier submitted). They pointed to Q2 metrics that underpin this plan: revenue of $10.0M (+11% sequential), international medical $5.8M (~58% of revenue, +26% sequential) with Germany +45% sequential/+33% YoY, Canadian medical $2.3M (from $3.0M), Canadian adult use $1.5M (+34% sequential); gross profit $4.3M (43% margin, +30% vs Q1, +13% YoY); operating expenses $4.0M (‑44% YoY, ‑4% sequential); adjusted EBITDA +$0.9M (second consecutive positive quarter, best since 2019) and positive net income (first profitable quarter since 2019). They also reiterated balance‑sheet flexibility to fund growth with $9.9M cash, virtually no debt, ownership of 2 facilities appraised >$15M, Q1 restructuring to deliver >$1M annualized savings, plans to mitigate the VAC reimbursement cut (30% reduction from $8.50 to $6/gram) via cost, supply‑chain and mix actions, and expected H2 shipments/replenishments for Brazil and New Zealand.